Mon, May 14, 2012
Sun, May 13, 2012
Sat, May 12, 2012
Fri, May 11, 2012
Thu, May 10, 2012
Wed, May 9, 2012
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012
Thu, May 3, 2012
[ Thu, May 03rd 2012 ] - Market Wire
00 p.m. EDT
Wed, May 2, 2012
Tue, May 1, 2012
Mon, April 30, 2012
[ Mon, Apr 30th 2012 ] - Market Wire
Hologic to Acquire Gen-Probe
Sun, April 29, 2012
Sat, April 28, 2012
Fri, April 27, 2012

Trimel Pharmaceuticals Corporation to Report First Quarter 2012 Results and Host A Conference Call to Update Investors


//health-fitness.news-articles.net/content/2012/ .. -host-a-conference-call-to-update-investors.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


May 07, 2012 16:36 ET

Trimel Pharmaceuticals Corporation to Report First Quarter 2012 Results and Host A Conference Call to Update Investors

TORONTO, ONTARIO--(Marketwire - May 7, 2012) - Trimel Pharmaceuticals Corporation (TSX:TRL) (the "Company" or "Trimel") will report on the first quarter financial results for the Company and its subsidiaries for the period ended March 31, 2012 on Tuesday May 8, 2012 after the market closes.

Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Wednesday, May 9, 2012, at 8:30 a.m. Eastern Daylight Time. Presenting from Trimel will be Bruce Brydon, Chairman of the Board and Chief Executive Officer, Tom Rossi, President and Chief Operating Officer and Kenneth Howling, Chief Financial Officer.

To access the call live, please dial 416-340-2218 (Toronto), 1-866-226-1793 (Canada and U.S.), and 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Time on Wednesday, May 16, 2012 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 7046128#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chief Executive Officer at 416 679-0711 or Kenneth Howling, Chief Financial Officer at 416 679-0536 or via email at [ ir@trimelpharmaceuticals.com ].

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit [ www.trimelpharmaceuticals.com ].




Publication Contributing Sources